Advertisement
AMRN vs HRTX
Which Stock Would AI Choose? Amarin Corporation (AMRN) vs. Heron Therapeutics (HRTX) Stock Comparison
Key Takeaways
- Amarin is a debt-free, single-product cardiovascular company (Vascepa/Vazkepa) with roughly $300 million in cash, while Heron carries meaningful debt and faces near-term patent and liquidity pressures.
- Heron offers a diversified acute-care and oncology portfolio with fast-growing products such as ZYNRELEF and APONVIE, but its lead oncology drug CINVANTI was hit by an adverse patent ruling and its 2026 guidance was withdrawn.
- Amarin's revenue is declining under generic and pricing pressure, but cost-cutting and international partnerships are driving earlier-than-expected positive cash flow.
- Relative performance has diverged sharply: Amarin has traded in a relatively stable range, while Heron shares have fallen substantially amid legal and strategic uncertainty.
- Market sentiment currently favors Amarin's balance-sheet stability over Heron's growth story, which remains clouded by unresolved catalysts.
- For more detail, explore AMRN Major News and AMRN Today's Price Move, as well as HRTX Major News and HRTX Today's Price Move.
- To see how automated systems are positioning across these and thousands of other tickers, explore Trending AI Robots.
Introduction
Both AMRN and HRTX are small-cap, commercial-stage pharmaceutical names, yet they sit at very different points in their respective life cycles. Amarin Corporation is a cardiovascular specialist defending a single flagship product against generics, while Heron Therapeutics is a multi-product biotech trying to shift its revenue mix toward faster-growing acute-care therapies. This stock comparison is most relevant to traders and investors weighing balance-sheet strength and stability against growth potential and binary legal risk. Understanding the relative performance and market positioning of these two tickers can help clarify which risk profile better fits a given portfolio.
AMRN Overview and Recent Performance
AMRN, or Amarin Corporation plc, is a Dublin-headquartered pharmaceutical company built around VASCEPA (known as VAZKEPA in Europe), an icosapent ethyl therapy approved to lower cardiovascular risk and treat severe hypertriglyceridemia (elevated triglycerides, or TG, in the blood). Revenue has been under pressure from generic competition and U.S. pricing and reimbursement headwinds, with quarterly product revenue declining year over year in recent periods.
In response, Amarin has pivoted to a leaner, internationally partnered model. It signed a long-term European commercialization agreement with Recordati and has now struck partnerships covering close to 100 markets. Management has also implemented a restructuring that reduced its workforce by roughly 40%, targeting about $70 million in operating-expense reductions. These efforts helped Amarin achieve positive cash flow earlier than previously expected, and the company ended recent periods with approximately $300 million in cash and investments and no debt. Separately, the U.S. Supreme Court agreed to hear a "skinny label" patent dispute involving VASCEPA, a legal development with potentially broad implications for generic drug makers. Despite strong relative stability, analysts remain cautious, with several maintaining price targets below the stock's recent trading range.
HRTX Overview and Recent Performance
HRTX, or Heron Therapeutics, Inc., is a commercial-stage biotechnology company focused on acute-care and oncology supportive-care products. Its portfolio includes ZYNRELEF, a non-opioid postsurgical pain treatment; APONVIE, an intravenous therapy for postoperative nausea; CINVANTI, an oncology supportive-care drug; and SUSTOL, which the company is winding down.
Heron's acute-care franchise has been a bright spot in recent quarters, with ZYNRELEF and APONVIE posting strong double-digit demand growth and benefiting from new permanent reimbursement codes. However, the company's outlook was disrupted when a court ruled adversely on CINVANTI patents, opening the door to potential generic competition. In response, Heron withdrew its full-year guidance, tightened spending, and disclosed that it is evaluating strategic alternatives. This combination of legal uncertainty and reduced visibility has driven a sharp reset in the share price, and at least one analyst downgraded the stock to a neutral rating while lowering price targets. Heron's balance sheet also carries debt, including notes payable and convertible notes, adding to the near-term risk profile.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of automated trading systems from a broader library of hundreds of AI trading bots that collectively monitor and trade thousands of different tickers. Only the bots judged most suitable for current market conditions are featured in this trending section. Each bot operates with its own trading style, strategy, timeframe, performance record, and universe of tickers, so the featured systems vary as market regimes shift. This diversity allows traders to evaluate approaches ranging from short-term momentum strategies to longer-horizon trend models, including systems that may be positioned in names such as AMRN and HRTX. Browsing the Trending AI Robots page can offer a useful, data-driven perspective on how automated systems are adapting to evolving conditions.
Head-to-Head Comparison
The clearest contrast between AMRN and HRTX lies in financial durability versus growth optionality. Amarin is a debt-free, cash-rich single-product company managing decline through cost discipline and international partnerships; its risk is concentrated in one drug facing generic and pricing pressure. Heron, by contrast, operates a more diversified portfolio with genuinely fast-growing acute-care products, but its near-term story is dominated by a patent setback on CINVANTI, withdrawn guidance, a debt load, and an open-ended strategic review.
In terms of momentum and sentiment, Amarin has held a relatively stable trading range as investors reward balance-sheet safety and positive cash flow, even as top-line revenue shrinks. Heron has experienced far more severe downside volatility, reflecting a repricing of its legal and liquidity risk. Sector exposure also differs: Amarin is tied to cardiovascular and lipid-management markets, while Heron spans surgical, postoperative, and oncology settings. Investors comparing these two names are essentially choosing between stability with limited near-term upside and a higher-risk turnaround with meaningful catalysts still unresolved.
Tickeron AI Verdict
Based on observable factors such as trend consistency, balance-sheet stability, and the clarity of near-term catalysts, Tickeron's AI would likely favor AMRN over HRTX in the current environment. Amarin's debt-free position, early positive cash flow, and more stable relative performance suggest a more predictable, lower-volatility profile, whereas Heron's adverse patent ruling, withdrawn guidance, and strategic-review process introduce elevated uncertainty. That said, this is a probabilistic assessment rather than a definitive forecast: Heron's acute-care growth could reassert itself if legal and strategic outcomes turn favorable, while Amarin still faces long-term erosion in its core franchise. A relative-positioning view would therefore lean toward Amarin for stability, while recognizing Heron as a higher-risk, catalyst-dependent alternative.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a StrongBuy and HRTX is a StrongBuy.
AMRN's Stochastic Oscillator sits in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMRN's RSI Oscillator exited the oversold zone, 25 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
Following a +1.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRN advanced for three days, in 183 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMRN as a result. In 80 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for AMRN turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 43 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
AMRN broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AMRN entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. AMRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.553) is normal, around the industry mean (-1.421). P/E Ratio (-9.675) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (3.220) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (1.554) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.
HRTX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for HRTX turned positive on November 09, 2026. Looking at past instances where HRTX's MACD turned positive, the stock continued to rise in 36 of 40 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 60 cases where HRTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on HRTX as a result. In 65 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +27.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTX advanced for three days, in 181 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
HRTX moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HRTX crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
HRTX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HRTX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.496) is normal, around the industry mean (3.498). P/E Ratio (-1.542) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.387) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. HRTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AMRN | HRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 100 | |
PRICE GROWTH RATING 1..100 | 62 | 81 | |
P/E GROWTH RATING 1..100 | 26 | 12 | |
SEASONALITY SCORE 1..100 | 50 | 27 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMRN's Valuation (63) in the Pharmaceuticals Other industry is in the same range as HRTX (78) in the Biotechnology industry. This means that AMRN’s stock grew similarly to HRTX’s over the last 12 months.
AMRN's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as HRTX (100) in the Biotechnology industry. This means that AMRN’s stock grew similarly to HRTX’s over the last 12 months.
AMRN's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as HRTX (100) in the Biotechnology industry. This means that AMRN’s stock grew similarly to HRTX’s over the last 12 months.
AMRN's Price Growth Rating (62) in the Pharmaceuticals Other industry is in the same range as HRTX (81) in the Biotechnology industry. This means that AMRN’s stock grew similarly to HRTX’s over the last 12 months.
HRTX's P/E Growth Rating (12) in the Biotechnology industry is in the same range as AMRN (26) in the Pharmaceuticals Other industry. This means that HRTX’s stock grew similarly to AMRN’s over the last 12 months.
| AMRN | HRTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 74% | N/A |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 87% |
| Advances ODDS (%) | 5 days ago 74% | 5 days ago 85% |
| Declines ODDS (%) | 2 days ago 85% | 2 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMRN’s FA Score shows that 1 FA rating(s) are green while HRTX’s FA Score has 1 green FA rating(s).
- AMRN’s FA Score: 1 green, 4 red.
- HRTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMRN’s TA Score shows that 3 TA indicator(s) are bullish while HRTX’s TA Score has 4 bullish TA indicator(s).
- AMRN’s TA Score: 3 bullish, 5 bearish.
- HRTX’s TA Score: 4 bullish, 5 bearish.
Price Growth
AMRN (@Pharmaceuticals: Major) experienced а -1.98% price change this week, while HRTX (@Biotechnology) price change was +5.97% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.36%. For the same industry, the average monthly price growth was +2.44%, and the average quarterly price growth was +6.83%.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
Reported Earning Dates
HRTX is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (+1.36% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AMRN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMRN has been loosely correlated with CNTB. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRN jumps, then CNTB could also see price increases.
| Ticker / NAME | Correlation To AMRN | 1D Price Change % | ||
|---|---|---|---|---|
| AMRN | 100% | -2.49% | ||
| CNTB - AMRN | 55% Loosely correlated | +1.79% | ||
| HRTX - AMRN | 44% Loosely correlated | -4.73% | ||
| MGNX - AMRN | 44% Loosely correlated | -3.93% | ||
| ALXO - AMRN | 43% Loosely correlated | -3.70% | ||
| ARWR - AMRN | 40% Loosely correlated | +1.34% | ||
More | ||||
HRTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, HRTX has been loosely correlated with FULC. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if HRTX jumps, then FULC could also see price increases.
| Ticker / NAME | Correlation To HRTX | 1D Price Change % | ||
|---|---|---|---|---|
| HRTX | 100% | -4.73% | ||
| FULC - HRTX | 47% Loosely correlated | +2.45% | ||
| ABVX - HRTX | 44% Loosely correlated | -2.90% | ||
| AMRN - HRTX | 44% Loosely correlated | -2.49% | ||
| SION - HRTX | 41% Loosely correlated | -2.92% | ||
| TENX - HRTX | 40% Loosely correlated | +0.62% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| XOEX | 41.06 | 0.05 | +0.12% |
| Xtrackers S&P 100 Ex Top 20 ETF (XOEX) | |||
| NFEB | 30.68 | N/A | N/A |
| Innovator Growth-100 Power Buffer ETF - February (NFEB) | |||
| BUFX | 22.70 | -0.02 | -0.11% |
| FT Vest Laddered Enhance & Moderate Buffer ETF (BUFX) | |||
| PCY | 20.19 | -0.04 | -0.20% |
| Invesco Emerging Markets Sovereign Debt ETF (PCY) | |||
| CBOT | 21.11 | -0.26 | -1.21% |
| Corgi Robots & Humanoids ETF (CBOT) | |||